FeNO 350 mL/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma—A Pilot Study
Advances in Respiratory Medicine · 2025
DOI: 10.3390/arm93050037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Respiratory Medicine, 2025. Verfasst von Vitaliano Nicola Quaranta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy. Hauptthemen laut MEDLINE: Asthma, Nitric Oxide, Anti-Asthmatic Agents, Fractional Exhaled Nitric Oxide Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Several studies focused on the importance of managing small airways disease in the treatment of severe asthma, whose improvement can improve respiratory symptoms, lung function, and airways inflammation, potentially reaching the objective of clinical remission.
Methods
Twenty-five patients with severe asthma and without bronchiectasis were enrolled. They were started on biological therapies with Omalizumab, Dupilumab, Benralizumab or Mepolizumab. Follow-up evaluations were conducted at baseline (T0) and after one year of biological therapy (T1). Assessments included clinical evaluations, spirometry, questionnaires, and inflammatory markers.
Results
Predictive analysis identified baseline FeNO 350 mL/s levels as a significant predictor of clinical remission in both univariable and multivariable analysis. Higher FeNO 350 mL/s levels at T0 were associated with an increased likelihood of achieving remission (p = 0.012). The optimal cutoff value for FeNO 350 mL/s was determined to be 18 ppb, based on the Younden Index.
Conclusions
Following patients with severe asthma on biological therapy for one year, FeNO 350 mL/s could be used as a predictive factor of clinical remission, highlighting its importance as inflammatory marker not only in small airways disease, but also in predicting clinical remission in severe asthmatic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Respiratory Disease, University of Bari, 70124 Bari, Italy.
ORCID-Profile: Vitaliano Nicola Quaranta, Andrea Portacci, Silvano Dragonieri
Zitieren
APA
Quaranta, V. N., Portacci, A., Maselli, L., Tornesello, M., Granito, M., Rociola, G., Dragonieri, S., & Carpagnano, G. E. (2025). FeNO 350 mL/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma—A Pilot Study. Advances in Respiratory Medicine. https://doi.org/10.3390/arm93050037
Vancouver
Quaranta VN, Portacci A, Maselli L, Tornesello M, Granito M, Rociola G, et al. FeNO 350 mL/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma—A Pilot Study. Advances in Respiratory Medicine. 2025. doi:10.3390/arm93050037
BibTeX
@article{Quaranta2025,
author = {Quaranta, Vitaliano Nicola and Portacci, Andrea and Maselli, Leonardo and Tornesello, Marta and Granito, Maria and Rociola, Gennaro and Dragonieri, Silvano and Carpagnano, Giovanna Elisiana},
title = {FeNO 350 mL/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma—A Pilot Study},
journal = {Advances in Respiratory Medicine},
year = {2025},
doi = {10.3390/arm93050037}
}
EUVIMED